Adis Drug Clinical Q&A

Molecular Diagnosis & Therapy

, Volume 17, Issue 1, pp 57-62


A Guide to Its Use in First-Line Treatment of Non-Small-Cell Lung Cancer with Epidermal Growth Factor-Activating Mutations

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


In the EU, the approved use of erlotinib (Tarceva®), an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, has recently been expanded to include first-line treatment of locally advanced or metastatic non-small-cell lung cancer (NSCLC) in patients with EGFR-activating mutations. In randomized, open-label, phase III clinical trials, oral erlotinib reduced the risk of progression, improved response rates, and was well tolerated relative to standard platinum-based doublet chemotherapy in Caucasian and Asian populations with advanced NSCLC with EGFR-activating mutations.